This WilmerHale webinar series is designed to provide pharmaceutical companies with a detailed overview of the new Food & Drug Administration Amendments Act of 2007, a forecast of its impact on all aspects of regulatory compliance and product development, as well as practical tips to prepare for implementation of the new regulatory requirements.
In this third session, topics of discussion will include clinical trial databank expansion and potential policy issues.
We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.
